Ion Beam Applications Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Ion Beam Applications hat ein Gesamteigenkapital von €106.2M und eine Gesamtverschuldung von €13.6M, wodurch sich der Verschuldungsgrad auf 12.8% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen €597.5M bzw. €491.3M. Ion Beam Applications Das EBIT des Unternehmens beträgt €7.5M, so dass der Zinsdeckungsgrad -23.1 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von €109.6M.

Wichtige Informationen

12.8%

Verhältnis von Schulden zu Eigenkapital

€13.58m

Verschuldung

Zinsdeckungsgrad	-23.1x
Bargeld	€109.62m
Eigenkapital	€106.21m
Gesamtverbindlichkeiten	€491.32m
Gesamtvermögen	€597.53m

Jüngste Berichte zur Finanzlage

Recent updates

It's Unlikely That The CEO Of Ion Beam Applications SA (EBR:IBAB) Will See A Huge Pay Rise This Year

Jun 06

Further Upside For Ion Beam Applications SA (EBR:IBAB) Shares Could Introduce Price Risks After 29% Bounce

Mar 25

Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?

Nov 07

Ion Beam Applications (EBR:IBAB) Has Some Way To Go To Become A Multi-Bagger

Oct 05

Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency

Jan 31

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Sep 28

Here's Why Shareholders May Want To Be Cautious With Increasing Ion Beam Applications SA's (EBR:IBAB) CEO Pay Packet

Jun 01

Ion Beam Applications' (EBR:IBAB) Returns On Capital Are Heading Higher

May 29

Does Ion Beam Applications SA (EBR:IBAB) Have A Place In Your Dividend Stock Portfolio?

Apr 20

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Mar 30

Should You Use Ion Beam Applications' (EBR:IBAB) Statutory Earnings To Analyse It?

Feb 10

What Type Of Shareholders Make Up Ion Beam Applications SA's (EBR:IBAB) Share Registry?

Jan 06

Does This Valuation Of Ion Beam Applications SA (EBR:IBAB) Imply Investors Are Overpaying?

Dec 10

Ion Beam Applications' (EBR:IBAB) Shareholders Are Down 64% On Their Shares

Nov 17

Ion Beam Applications SA (EBR:IBAB) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Aug 20

Estimating The Intrinsic Value Of Ion Beam Applications SA (EBR:IBAB)

Jul 21

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: IBABDie kurzfristigen Aktiva des Unternehmens (€452.0M) decken seine kurzfristigen Passiva (€452.6M) nicht.

Langfristige Verbindlichkeiten: IBABDie kurzfristigen Vermögenswerte des Unternehmens (€452.0M) übersteigen seine langfristigen Verbindlichkeiten (€38.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: IBAB über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: IBAB Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 69.8% auf 12.8% zurückgegangen.

Schuldendeckung: IBABDer operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: IBAB mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

Ion Beam Applications Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Recent updates

Dividend of €0.12 announced

It's Unlikely That The CEO Of Ion Beam Applications SA (EBR:IBAB) Will See A Huge Pay Rise This Year

Price target increased by 12% to €17.50

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Further Upside For Ion Beam Applications SA (EBR:IBAB) Shares Could Introduce Price Risks After 29% Bounce

Full year 2023 earnings released

Ion Beam Applications SA to Report First Half, 2024 Results on Aug 29, 2024

Ion Beam Applications S.A., CMI Inc. and Life Molecular Imaging Announce Japanese Approval for the Reimbursement of Amyloid-Pet Diagnostic Neuraceq in Alzheimer's Disease

Consensus EPS estimates fall by 20%

Ion Beam Applications SA, Annual General Meeting, Jun 12, 2024

Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?

New minor risk - Share price stability

Ion Beam Applications S.A Plans Total System Restoration on its First-Ever Proton Therapy Installation

Price target decreased by 18% to €18.00

Insufficient new directors

Price target increased by 26% to €22.30

Full year 2022 earnings released

Ion Beam Applications SA to Report Q1, 2023 Results on May 18, 2023

Price target increased to €19.25

Ion Beam Applications (EBR:IBAB) Has Some Way To Go To Become A Multi-Bagger

First half 2022 earnings released: €0.059 loss per share (vs €0.066 loss in 1H 2021)

Ion Beam Applications SA Continues to Shape the Future of Proton Therapy At Estro 2022 Annual Congress

Ion Beam Applications SA (ENXTBR:IBAB) acquired Modus Medical Devices Inc.

Full year 2021 earnings: EPS exceeds analyst expectations

Price target increased to €17.75

Investor sentiment improved over the past week

Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency

IBA Launches Compact Low-Energy Cyclotron, Cyclone® KEY

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

First half 2021 earnings released

Ion Beam Applications S.A. Announces Launch of a Large-Scale, Multi-Institutional, Randomized Controlled Clinical Trial

Price target increased to €15.00

Here's Why Shareholders May Want To Be Cautious With Increasing Ion Beam Applications SA's (EBR:IBAB) CEO Pay Packet

Ion Beam Applications' (EBR:IBAB) Returns On Capital Are Heading Higher

Does Ion Beam Applications SA (EBR:IBAB) Have A Place In Your Dividend Stock Portfolio?

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Full year 2020 earnings released

IBA (Ion Beam Applications S.A. and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)

Ion Beam Applications SA Receives Down Payment from National Cancer Center Korea for A Second Proteus® System

Should You Use Ion Beam Applications' (EBR:IBAB) Statutory Earnings To Analyse It?

Price target raised to €12.60

Ion Beam Applications SA to Report Q3, 2021 Results on Nov 18, 2021

New 90-day high: €13.46

What Type Of Shareholders Make Up Ion Beam Applications SA's (EBR:IBAB) Share Registry?

Does This Valuation Of Ion Beam Applications SA (EBR:IBAB) Imply Investors Are Overpaying?

Ion Beam Applications' (EBR:IBAB) Shareholders Are Down 64% On Their Shares

New 90-day high: €11.96

New 90-day high: €11.68

Ion Beam Applications SA Signs Contract for the First End-To-End Rhodotron® Duo Solution for Multi-Purpose Irradiation in Taiwan

Ion Beam Applications SA Announces First Payment of EUR 20 Million Received for Strategic Licensing Deal in China

New 90-day high: €10.60

Ion Beam Applications SA to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day low - €7.14

Ion Beam Applications SA (EBR:IBAB) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

New 90-day low - €7.30

Estimating The Intrinsic Value Of Ion Beam Applications SA (EBR:IBAB)

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen